EN | TR
E-ISSN: 2147-673X
Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
PDF
Cite
Share
Request
RESEARCH ARTICLE
VOLUME: 9 ISSUE: 1
P: 3-3
January 2020

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Mediterr J Infect Microb Antimicrob 2020;9(1):3-3
DOI: 10.4274/mjima.galenos.2020.2020.3
Müge AYHAN 1
Bircan KAYAASLAN 2
İmran HASANOĞLU 2
Ayşe KAYA KALEM 2
Dilek ASİLTÜRK 2
Mehmet Akın TAŞYARAN 2
Hatice Rahmet GÜNER 2
1. Ankara Atatürk Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
2. Ankara Yıldırım Beyazıt University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
No information available.
No information available
PDF
Cite
Share
Request

Summary

Introduction: Infections with extended-spectrum beta-lactamase (ESBL)-producing strains are seen at increasing rates, resulting in increased morbidity, mortality, length of hospitalization, and cost. Effective and safe treatment of these infections is important. The aim of this study was to compare the effectiveness of piperacillin-tazobactam (PTZ) and carbapenems in nosocomial infections with ESBL-producing Escherichia coli and Klebsiella pneumoniae in hospitalized patients.
Materials and Methods: This study was performed retrospectively on patients who were infected with ESBL-producing E. coli and K. pneumoniae while hospitalized in Ankara Atatürk Tranining and Research Hospital between 2014 and 2017. Both PTZ- and carbapenem-susceptible isolates were included in the study. Patients with signs of infection who were older than 18 years, hospitalized for at least 48 hours, and received PTZ or carbapenem therapy were included in the study. Patients who received PTZ and carbapenem antibiotics consecutively in same infectious episode, received another antibiotic active against ESBL-producing microorganisms, received the selected antibiotic for less than 48 hours, or had polymicrobial infection were excluded from the study. Demographic characteristics, comorbid diseases, antibiotics used and their dose/duration, mechanical ventilation, presence of central catheter, clinical and microbiological responses to treatment, and end-of-treatment and 30-day mortality were recorded and compared.
Results: Of the total 113 patients, 60 (53.1%) were male and the mean age was 66.14±18.2 years. Of the patients, 73.5% had E. coli and 26.5% had K. pneumoniae. Seventy patients (61.9%) received carbapenem and 43 patients (38.1%) received PTZ treatment. Microbiological eradication rate was 71.7% (43/60) in patients with control cultures. Clinical response was observed in 72.6% of the cases. The overall mortality rate was 31.0% (n=35). There were no significant differences between the groups in clinical and microbiological response (p=0.055; p=0.303) or end-of-treatment and 30-day mortality (p=0.180, p=0.288). Age and bacteremia was found to be independent risk factors for mortality (p=0.006 for both).
Conclusion: PTZ is an important alternative for infections caused by ESBL-producing microorganisms. In recent years, the need for rational antibiotic use has increased and carbapenem-sparing treatments have became more important. Piperacillin-tazobactam is one of the best alternatives and has comparable effectiveness in infections caused by ESBL-producing E. coli and Klebsiella spp.

Keywords:
Extended-spectrum beta-lactamase, carbapenems, piperacillin-tazobactam, Escherichia coli, Klebsiella pneumoniae

References

1
Sfeir MM, Askin G, Christos P. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum betalactamase- producing Enterobacteriaceae: systematic review and metaanalysis. Int J Antimicrob Agents. 2018;52:554-70.
2
Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, De Pascale G, Proli EM, Cauda R, Cicchetti A, Fadda G. Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum- -Lactamase Production and Inadequate Initial Antibiotic Therapy. Antimicrob Agents Chemother. 2010;54:4085-91.
3
Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris- Brown T, Paterson DL. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone nonsusceptible Escherichia coli and Klebsiella spp. (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015;16:24.
4
Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis. 2017;64:972-80.
5
Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. PLoS One. 2016;11:e0153696.
6
Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase– producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014;80:222-6.
7
Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D’Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T. Bloodstream Infections Caused by Extended-Spectrum- -Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrob Agents Chemother. 2008;52:3244-52.
8
Wollheim C, Guerra IM, Conte VD, Hoffman SP, Schreiner FJ, Delamare AP, Barth AL, Echeverrigaray S, Costa SO. Nosocomial and community infections due to class A extended-spectrum β-lactamase (ESBLA)-producing Escherichia coli and Klebsiella spp. in southern Brazil. Braz J Infect Dis. 2011;15:138-43.
9
Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D. Carbapenems Versus Piperacillin- Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36:981-5.
10
López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillintazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect. 2010;16:132-6.
11
Sugimoto N, Yamagishi Y, Mikamo H. Proposed breakpoint of piperacillin/ tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia. J Infect Chemother. 2017;23:65-7.
12
D’Angelo RG, Johnson JK, Bork JT, Heil EL. Treatment options for extendedspectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17:953-67.
13
Watkins RR, Deresinski S. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15:893-5.
14
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group. Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin- Tazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia. Clin Infect Dis. 2015;60:1319-25.
15
Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; M100, CLSI, (2013-2016). Available from: https://clsi.org/media/2663/m100ed29_sample.pdf
16
Centers for Disease Control and Prevention (CDC). Last Accessed Date: 8.05.2019. Available from: https://www.cdc.gov/nhsn/PDFs/ pscManual/4PSC_CLABScurrent.pdf
17
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16:128-40.
18
Centers for Disease Control and Prevention (CDC). Last Accessed Date: 08.05.2019. Available from: https://www.cdc.gov/nhsn/PDFs/ pscManual/2PSC_IdentifyingHAIs_NHSNcurrent.pdf
19
Seifert H, Cornely O, Seggewiss K, Decker M, Stefanik D, Wisplinghoff H. Bloodstream infection in neutropenic cancer patients related to short-termnontunnelled catheters determined by quantitative blood cultures,differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J Clin Microbiol. 2003;41:118–23.
20
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10-52.
21
Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297:1478-88.
22
McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, Blevins AE, Diekema D, Chiang HY, Nair R, Perencevich E. Incidence of Extended- Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. Infect Control Hosp Epidemiol. 2017;38:1209-15.
23
Pana ZD, Zaoutis T. Treatment of extended-spectrum β-lactamaseproducing Enterobacteriaceae (ESBLs) infections: what have we learned until now?. F1000Res. 2018;7. pii: F1000 Faculty Rev-1347.
24
Adler A, Katz DE, Marchaim D. The continuing plague of extended-spectrum B-lactamase-producing Enterobacteriaceae infections. Infect Dis Clin North Am 2016;30:347-75.
25
Perez LRR, Narvaez GA. Understanding the β-Lactam/Inhibitor of β-Lactamase Combinations: Reassessment for Better Antimicrobial Stewardship. Infect Control Hosp Epidemiol. 2017;38:881-3.
26
Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem Resistance Among Klebsiella pneumoniae Isolates Risk Factors, Molecular Characteristics, and Susceptibility Patterns. Infect Control Hosp Epidemiol. 2009;30:666-71.
27
Schuetz AN, Reyes S, Tamma PD. Point-Counterpoint: Piperacillin- Tazobactam Should Be Used To Treat Infections with Extended-Spectrum- Beta-Lactamase-Positive Organisms. J Clin Microbiol. 2018;56:e01917-7.
28
Sönmez U, Çalık Ş, Çayıröz MU, Olut AI, Arı A, Tosun S, Yiş R. Genişlemiş Spektrumlu Beta-Laktamaz Salgılayan Klebsiella pneumoniae ve Escherichia coli’ye Bağlı Bakteriyemilerde Mortalite ile İlişkili Risk Faktörlerinin Belirlenmesi ve Ampirik Piperasilin-Tazobaktam ile Karbapenem Tedavisi Sonuçlarının Karşılaştırılması. Ankem Derg. 2018;32:1-8.
29
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793-803.
30
Son SK, Lee NR, Ko JH, Choi JK, Moon SY, Joo EJ, Peck KR, Park DA. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:2631-42.